News & Updates
Filter by Specialty:
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
12 Apr 2023
byStephen Padilla
Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
12 Apr 2023
QUARTZ3 data make a case for using ivarmacitinib in atopic dermatitis
04 Apr 2023
byJairia Dela Cruz
Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.